Barr Sues FDA Over Exclusivity for Generic Allegra-D
Barr Laboratories has mounted a challenge to the way the U.S. Food and Drug Administration awards marketing exclusivity for new generics with a lawsuit seeking 180 days of exclusivity for its...To view the full article, register now.
Already a subscriber? Click here to view full article